Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in $75 Million At-The-Market Offering
Press Release – New York, NY – May 26, 2020 – Sichenzia Ross Ference LLP announced today that it represented Relmada Therapeutics, Inc. (NASDAQ: “RLMD”), a clinical stage company developing therapies for depression and central nervous system disease, in a $75 million At-The-Market offering (“ATM”).
The shares were registered on RLMD’s Registration Statement on Form S-3 (File No. 333-234262) filed with the Securities and Exchange Commission on October 18, 2019, and declared effective by the SEC on October 31, 2019, and the prospectus supplement relating to the ATM filed with the SEC on May 15, 2020.
Jefferies LLC acted as agent for the ATM.
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia and Barrett DiPaolo.